Streetbeat News

NKGN

NKGen Biotech, Inc. Common Stock

https://www.grafacq.com

Industry

Biotechnology

Graf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas.

Open

0.26

Mkt cap

9.6M

Volume

270K

High

0.28

P/E Ratio

-0.08

52-wk high

4.06

Low

0.25

Div yield

N/A

52-wk low

0.20

NKGen Biotech shares are trading lower following the announcement of two poster presentations on its NK cell product, troculeucel, for Alzheimer's Disease.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 2:59 pm

NKGen Biotech presented promising Phase 1/2a data on Troculeucel for Alzheimer's at the CTAD Conference, showing biomarker reductions and cognitive improvements. The highest dose demonstrated safety and potential to delay dementia.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 12:07 pm

Spirit Airlines shares surged 43.5% in pre-market trading after modifying its card processing agreement, extending deadlines for its 2025 notes. Several other stocks, including GRI Bio and BioVie, also saw significant pre-market movements.

Portfolio Pulse from Avi Kapoor

October 21, 2024 | 11:03 am

Several health care stocks experienced significant price movements during Friday's intraday session. Notable gainers included Catheter Precision (AMEX:VTAK) with a 142.8% increase, and Tevogen Bio Holdings (NASDAQ:TVGN) with a 49.28% rise. On the losing side, NKGen Biotech (NASDAQ:NKGN) fell by 31.9%, and Orgenesis (NASDAQ:ORGS) declined by 28.05%.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 4:31 pm

U.S. stocks showed mixed performance with the Dow Jones falling over 100 points, while the NASDAQ and S&P 500 rose. Netflix reported strong Q3 results, surpassing revenue expectations and increasing its subscriber base. Several stocks experienced significant price movements, including Catheter Precision, Bright Minds Biosciences, and SOBR Safe, which saw substantial gains, while NKGen Biotech, Orgenesis, and NuZee faced declines.

Portfolio Pulse from Avi Kapoor

October 18, 2024 | 2:27 pm

In Friday's pre-market session, several health care stocks experienced significant price movements. Notable gainers included Catheter Precision (AMEX:VTAK) with a 151.9% increase, Akanda (NASDAQ:AKAN) up 71.13%, and Tenon Medical (NASDAQ:TNON) rising 39.06%. On the losing side, Orgenesis (NASDAQ:ORGS) fell 37.9%, Molecular Templates (NASDAQ:MTEM) dropped 30.11%, and NKGen Biotech (NASDAQ:NKGN) decreased by 29.02%.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 12:09 pm

Intuitive Surgical shares rose 6.9% in pre-market trading due to better-than-expected Q3 results and regulatory clearance in South Korea. Netflix also gained 5.8% after strong Q3 results. Several other stocks experienced significant pre-market movements.

Portfolio Pulse from Avi Kapoor

October 18, 2024 | 10:52 am

In Thursday's after-market session, several health care stocks experienced significant price movements. Notable gainers included Catheter Precision (VTAK) with a 71.1% increase, Tenon Medical (TNON) up 51.31%, and Akanda (AKAN) rising 38.14%. On the losing side, NKGen Biotech (NKGN) fell 35.0%, Molecular Templates (MTEM) dropped 12.95%, and Travere Therapeutics (TVTX) decreased by 11.03%.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 8:30 pm

In Monday's pre-market session, several healthcare stocks experienced significant movements. Scholar Rock Holding (SRRK) saw a massive increase of 198.1%, while Trevena (TRVN) experienced a sharp decline of 45.5%. Other notable gainers include LogicMark (LGMK) and Biohaven (BHVN), while Entero Therapeutics (ENTO) and Onconetix (ONCO) were among the losers.

Portfolio Pulse from Benzinga Insights

October 07, 2024 | 12:08 pm

In Friday's after-market session, several healthcare stocks experienced significant price movements. Prenetics Global, Chromocell Therapeutics, Nuwellis, MiNK Therapeutics, Accolade, and Tharimmune saw gains, while Trevena, Entero Therapeutics, NKGen Biotech, Kazia Therapeutics, Carmell, and Silexion Therapeutics experienced losses.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 8:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.